In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Acorn Cardiovascular (develops medical devices for heart failure) raised $20mm in a private placement of Series E preferred stock. Johnson & Johnson Development Corp. led the financing and was joined by return investors New Enterprise Associates, CSFB, Piper Jaffray Ventures, Three Arch Partners, Bessemer Venture Partners, Spray Venture Fund, and others.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?